Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Raw Materials (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Raw Materials over the past 7 years, most recently at $14.6 million for Q4 2018.

  • Quarterly results put Raw Materials at $14.6 million for Q4 2018, up 10.42% from a year ago — trailing twelve months through Nov 2018 was $14.6 million (up 10.42% YoY), and the annual figure for FY2018 was $15.3 million, up 50.48%.
  • Raw Materials for Q4 2018 was $14.6 million at Lifecore Biomedical, Inc. \De\, up from $13.9 million in the prior quarter.
  • Over the last five years, Raw Materials for LFCR hit a ceiling of $15.3 million in Q2 2018 and a floor of $4.2 million in Q4 2016.
  • Median Raw Materials over the past 5 years was $10.9 million (2014), compared with a mean of $11.2 million.
  • Biggest five-year swings in Raw Materials: tumbled 62.27% in 2016 and later skyrocketed 215.73% in 2017.
  • Lifecore Biomedical, Inc. \De\'s Raw Materials stood at $12.1 million in 2014, then fell by 8.15% to $11.1 million in 2015, then tumbled by 62.27% to $4.2 million in 2016, then skyrocketed by 215.73% to $13.2 million in 2017, then grew by 10.42% to $14.6 million in 2018.
  • The last three reported values for Raw Materials were $14.6 million (Q4 2018), $13.9 million (Q3 2018), and $15.3 million (Q2 2018) per Business Quant data.